PE20221510A1 - Neoantigenos expresados en cancer de ovario y sus usos - Google Patents

Neoantigenos expresados en cancer de ovario y sus usos

Info

Publication number
PE20221510A1
PE20221510A1 PE2022001731A PE2022001731A PE20221510A1 PE 20221510 A1 PE20221510 A1 PE 20221510A1 PE 2022001731 A PE2022001731 A PE 2022001731A PE 2022001731 A PE2022001731 A PE 2022001731A PE 20221510 A1 PE20221510 A1 PE 20221510A1
Authority
PE
Peru
Prior art keywords
ovarian cancer
neoantigens
neoantigens expressed
expressed
vaccines
Prior art date
Application number
PE2022001731A
Other languages
English (en)
Inventor
Vipul Bhargava
Vinod Krishna
David J Pocalyko
Pegah Safabakhsh
Manuel Alejandro Sepulveda
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20221510A1 publication Critical patent/PE20221510A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La descripcion se relaciona con neoantigenos del cancer de ovario, polinucleotidos que los codifican, vectores, celulas huesped, particulas de virus recombinantes, vacunas que comprenden los neoantigenos, moleculas proteinaceas que se unen a los neoantigenos del cancer de ovario, y metodos para elaborarlos y usarlos
PE2022001731A 2020-02-14 2021-02-12 Neoantigenos expresados en cancer de ovario y sus usos PE20221510A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976384P 2020-02-14 2020-02-14
PCT/IB2021/051184 WO2021161244A1 (en) 2020-02-14 2021-02-12 Neoantigens expressed in ovarian cancer and their uses

Publications (1)

Publication Number Publication Date
PE20221510A1 true PE20221510A1 (es) 2022-10-04

Family

ID=74669210

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001731A PE20221510A1 (es) 2020-02-14 2021-02-12 Neoantigenos expresados en cancer de ovario y sus usos

Country Status (21)

Country Link
US (1) US11945881B2 (es)
EP (1) EP4103222A1 (es)
JP (1) JP2023514566A (es)
KR (1) KR20220141848A (es)
CN (1) CN115515623A (es)
AR (1) AR121334A1 (es)
AU (1) AU2021220007A1 (es)
BR (1) BR112022016020A2 (es)
CA (1) CA3172756A1 (es)
CL (1) CL2022002187A1 (es)
CO (1) CO2022012327A2 (es)
CR (1) CR20220397A (es)
DO (1) DOP2022000167A (es)
EC (1) ECSP22071330A (es)
IL (1) IL295546A (es)
JO (1) JOP20220185A1 (es)
MX (1) MX2022009986A (es)
PE (1) PE20221510A1 (es)
TW (1) TW202144388A (es)
UY (1) UY39078A (es)
WO (1) WO2021161244A1 (es)

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US226A (en) 1837-06-03 Samuel goss
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US563536A (en) 1896-07-07 Bracket for swinging stages
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6011146A (en) 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP1489184A1 (en) 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
EP0833934B2 (en) 1995-06-15 2012-08-15 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
WO1998026048A1 (en) 1996-12-13 1998-06-18 Schering Corporation Methods for purifying viruses
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
DK0985039T3 (da) 1997-06-12 2008-06-09 Novartis Int Pharm Ltd Kunstige antistof-polypeptider
DE69840600D1 (de) 1997-09-16 2009-04-09 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t-zellen
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6440442B1 (en) 1998-06-29 2002-08-27 Hydromer, Inc. Hydrophilic polymer blends used for dry cow therapy
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
ATE445018T1 (de) 1999-05-17 2009-10-15 Crucell Holland Bv Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US20150329617A1 (en) 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
EP1601333B1 (en) 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
CA2537759C (en) 2003-09-05 2015-03-24 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
GB2408507B (en) 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
PL2163260T3 (pl) 2004-01-23 2017-12-29 Msd Italia S.R.L. Szympansie adenowirusowe nośniki szczepionek
EP1683808A1 (en) 2005-01-25 2006-07-26 Het Nederlands Kanker Instituut Means and methods for breaking noncovalent binding interactions between molecules
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP1878744A1 (en) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
GB2440529B (en) 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
NZ594355A (en) 2009-02-02 2012-11-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
EP2621523B1 (en) 2010-09-29 2017-08-09 UTI Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
EP2502934B1 (en) 2011-03-24 2018-01-17 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
CN103796680A (zh) 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
PT2771364T (pt) 2011-10-27 2019-09-10 Genmab As Produção de proteínas heterodiméricas
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
WO2013096291A2 (en) 2011-12-20 2013-06-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
CN105683215B (zh) 2013-06-26 2021-04-23 香雪生命科学技术（广东）有限公司 高稳定性的t细胞受体及其制法和应用
JP6788500B2 (ja) 2013-10-23 2020-11-25 アメリカ合衆国 Ｍｕｃ１−ｃ癌タンパク質のｈｌａ−ａ２４アゴニストエピトープ及び組成物及び使用方法
US9884075B2 (en) 2014-01-16 2018-02-06 California Institute Of Technology Domain-swap T cell receptors
US9750801B2 (en) 2014-02-28 2017-09-05 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
KR20180011135A (ko) 2015-05-06 2018-01-31 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
WO2016196691A2 (en) 2015-06-01 2016-12-08 California Institute Of Technology Compositions and methods for screening t cells with antigens for specific populations
WO2017015064A1 (en) 2015-07-20 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Detection phenotyping and quantitation of cells with multimeric binding reagent
MX2018002106A (es) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el hpv18.
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
EP3383893A4 (en) 2015-12-02 2019-06-26 Innovative Targeting Solutions Inc. T CELL RECEPTORS WITH VARIABLE SINGLE DOMAIN
US11446398B2 (en) * 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
BR112019007433A2 (pt) 2016-10-17 2019-07-02 Synthetic Genomics Inc sistemas de replicon de vírus recombinante e usos dos mesmos
EP3548625A2 (en) 2016-12-05 2019-10-09 Synthetic Genomics, Inc. Compositions and methods for enhancing gene expression
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
MX2020000221A (es) 2017-07-05 2020-08-13 Nouscom Ag Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
SG11202005772YA (en) 2018-01-06 2020-07-29 Emergex Vaccines Holding Ltd Mhc class i associated peptides for prevention and treatment of multiple flavi virus
AU2019210189A1 (en) 2018-01-19 2020-08-06 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
EP3773476A1 (en) 2018-03-30 2021-02-17 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CA3158692A1 (en) 2019-11-18 2021-05-27 Epivax Therapeutics, Inc. Improved neo-epitope vaccines and methods of treating cancer
CA3158646A1 (en) 2019-11-18 2021-05-27 Epivax Therapeutics, Inc. Improved compositions and methods for shared neo-epitope vaccines
WO2022189626A2 (en) 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides
CA3213004A1 (en) 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides and uses thereof

Also Published As

Publication number Publication date
CA3172756A1 (en) 2021-08-19
CN115515623A (zh) 2022-12-23
TW202144388A (zh) 2021-12-01
BR112022016020A2 (pt) 2022-10-11
WO2021161244A1 (en) 2021-08-19
CO2022012327A2 (es) 2022-09-20
AR121334A1 (es) 2022-05-11
UY39078A (es) 2021-08-31
EP4103222A1 (en) 2022-12-21
US20210261609A1 (en) 2021-08-26
KR20220141848A (ko) 2022-10-20
CL2022002187A1 (es) 2023-02-03
US11945881B2 (en) 2024-04-02
MX2022009986A (es) 2022-11-10
JOP20220185A1 (ar) 2023-01-30
ECSP22071330A (es) 2022-10-31
IL295546A (en) 2022-10-01
DOP2022000167A (es) 2023-01-15
CR20220397A (es) 2022-10-07
AU2021220007A1 (en) 2022-10-06
JP2023514566A (ja) 2023-04-06

Similar Documents

Publication Publication Date Title
CO2021010006A2 (es) Neoantígenos prostáticos y sus usos
CL2022003264A1 (es) Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
ECSP20075163A (es) Moléculas de unión contra bcma y usos de las mismas
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
AR105634A1 (es) Anticuerpos que se unen a il 8 y sus usos
PE20180672A1 (es) Anticuerpos anti-ctla-4 y metodos de uso de los mismos
BR112017023131A2 (pt) anticorpos anti- fcrn
NI201900034A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y uso de los mismos
CR20150547A (es) Anticuerpos anti-cd52
CO2020014515A2 (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
UY39079A (es) Neoantígenos expresados en mieloma múltiple y sus usos
UY39345A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
PE20221510A1 (es) Neoantigenos expresados en cancer de ovario y sus usos
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
UY36616A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
AR117798A1 (es) Neoantígenos prostáticos y sus usos
UY39669A (es) Usos de anticuerpos cd79b para aplicaciones terapéuticas autoinmunitarias
CO2022019183A2 (es) Construcciones anti-cd93 y usos de las mismas
AR119440A1 (es) Anticuerpos inmunomoduladores y métodos de uso de los mismos
EA202191919A1 (ru) Неоантигены предстательной железы и их применение
BR112018074710A2 (pt) método para fabricação de objetos tridimensionais e aparelho para o mesmo